Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog.
Yoshihito UchidaMasamitsu NakaoShunsuke YamadaShohei TsujiHayato UemuraJun-Ichi KouyamaKayoko NaikiKayoko SugawaraNobuaki NakayamaYukinori ImaiTomoaki TomiyaSatoshi MochidaPublished in: PloS one (2022)
Switching of the nucleos(t)ide analog used for treatment from ETV to TAF merits consideration in patients with chronic HBV infection, since the extent of reduction of the serum HBsAg level was greater during the TAF treatment period than during the ETV treatment period.